Biomarkers with a mechanistic focus

JAMA Psychiatry

Volumn 72, Issue 7, 2015, Pages 633-634

  Pine, Daniel S ^a   Leibenluft, Ellen ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TRASTUZUMAB;

AMYGDALOID NUCLEUS; AUTISM; BREAST CANCER; CLINICAL RESEARCH; HUMAN; MENTAL DISEASE; NEUROIMAGING; NONHUMAN; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; RESEARCH PRIORITY; SCHIZOPHRENIA; SHORT SURVEY; SURVIVAL; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME; METABOLISM;

BIOLOGICAL MARKERS; HUMANS; MENTAL DISORDERS;

EID: 84937422811     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2015.0498     Document Type: Short Survey

References (8)

1. Wilson M. DSM-III and the transformation of American psychiatry: a history. Am J Psychiatry. 1993;150(3):399-410.
2. Paulus MP. Pragmatism instead of mechanism: a call for impactful biological psychiatry [published onlineMay 20, 2015]. JAMA Psychiatry. doi:10.1001/jamapsychiatry.2015.0497.
3. Kapur S, Phillips AG, Insel TR.Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol Psychiatry. 2012; 17(12):1174-1179.
4. Kraemer HC, Lowe KK, Kupfer DJ. To Your Health: Howto Understand What Research Tells Us About Risk. London, England: Oxford University Press; 2005.
5. Roesch MR, Calu DJ, Esber GR, Schoenbaum G. All that glitters: dissociating attention and outcome expectancy from prediction errors signals. J Neurophysiol. 2010;104(2):587-595.
6. Davis M, Whalen PJ. The amygdala: vigilance and emotion. Mol Psychiatry. 2001;6(1):13-34.
7. Pine DS, Fox NA. Childhood antecedents and risk for adult mental disorders. Annu Rev Psychol. 2015; 66:459-485.
8. Hudis CA. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med. 2007;357 (1):39-51.